Coeptis Therapeutics' Phase 1 Data on DVX201 for COVID-19 Accepted in Molecular Therapy

In an announcement from Coeptis Therapeutics Holdings, Inc., the biopharmaceutical company disclosed positive results from a Phase 1 clinical trial evaluating DVX201 for treating hospitalized COVID-19 patients. This trial's outcomes have been accepted for publication in the journal Molecular Therapy Methods and Clinical Development.

DVX201 is described as the first allogeneic natural killer (NK) cell therapy derived from pooled donor cord blood CD34+ cells. This adoptive immunotherapy aims to tackle barriers in the allogeneic cell therapy space by offering a scalable and consistent treatment solution. A total of nine patients received DVX201 without experiencing dose-limiting toxicities, cytokine release syndrome, or infusion-related toxicities.

Key findings from the study underscore the safety and feasibility of DVX201 in treating active SARS-CoV-2 infections. The manuscript detailing these results marks the first known demonstration of the safety of adoptive immunotherapy using off-the-shelf NK cells specifically in COVID-19 patients, particularly those at high risk of disease progression. Notably, the treatment was well-tolerated, and no treatment-related adverse events were observed.

Observations from the study included rapid improvements in patients’ oxygenation levels, enhanced pulmonary radiographic findings, and discharge from the hospital within days following the infusion. These outcomes support the potential of allogeneic NK cell therapy not only as a promising treatment for COVID-19 but also as a scalable, stockpile-ready antiviral strategy for addressing future viral outbreaks.

Dr. Joshua Hill, an associate professor and physician at Fred Hutch Cancer Center and corresponding author of the study, emphasized the significance of these findings. He highlighted the ongoing need for additional therapeutic options for COVID-19, especially among immunocompromised individuals. While the study was not designed to assess efficacy, it demonstrated the safety and potential utility of NK cell therapy as a complementary strategy for treating viral infections in high-risk patients.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed excitement over the results and the opportunity to share the full findings in the forthcoming publication. He noted that these positive outcomes, along with a recently announced expanded license agreement with Deverra, strengthen Coeptis' role in combating infectious diseases.

The acceptance of these study results for publication in a reputable journal represents a significant milestone for Coeptis Therapeutics in their mission to develop innovative cell therapy platforms. Their product portfolio highlights assets licensed from Deverra Therapeutics, including DVX201, and a universal multi-antigen CAR T technology (SNAP-CAR), which could disrupt conventional treatment paradigms and improve patient outcomes.

The study's results provide a promising outlook for the future of NK cell therapy in managing not only COVID-19 but potentially other viral infections as well. This development aligns with Coeptis Therapeutics' broader strategy to maximize the value of their product portfolio through strategic partnerships and in-license agreements aimed at advancing treatments for cancer and infectious diseases.